

UC San Diego

UC San Diego Previously Published Works

Title

Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.

Permalink

<https://escholarship.org/uc/item/2zr0z8s1>

Journal

Nature Medicine, 29(12)

Authors

Black, Lora

Boggess, Blake

Chatterjee, Paramita

et al.

Publication Date

2023-12-01

DOI

10.1038/s41591-023-02632-w

Peer reviewed

# Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial

Received: 13 April 2023

Accepted: 5 October 2023

Published online: 2 November 2023

 Check for updates


Ken Mautner<sup>1,12</sup>✉, Michael Gottschalk<sup>1,12</sup>, Scott D. Boden<sup>1</sup>, Alison Akard<sup>1</sup>, Won C. Bae<sup>2</sup>, Lora Black<sup>3</sup>, Blake Boggess<sup>4</sup>, Paramita Chatterjee<sup>5</sup>, Christine B. Chung<sup>2</sup>, Kirk A. Easley<sup>6</sup>, Greg Gibson<sup>7</sup>, Josh Hackel<sup>8</sup>, Katie Jensen<sup>3</sup>, Linda Kippner<sup>5</sup>, Chad Kurtenbach<sup>3</sup>, Joanne Kurtzberg<sup>9</sup>, R. Amadeus Mason<sup>1</sup>, Benjamin Noonan<sup>10</sup>, Krishnendu Roy<sup>11</sup>, Verle Valentine<sup>3</sup>, Carolyn Yeago<sup>5</sup> & Hicham Drissi<sup>1</sup>✉

Various types of cellular injection have become a popular and costly treatment option for patients with knee osteoarthritis despite a paucity of literature establishing relative efficacy to each other or corticosteroid injections. Here we aimed to identify the safety and efficacy of cell injections from autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic human umbilical cord tissue-derived mesenchymal stromal cells, in comparison to corticosteroid injection (CSI). The study was a phase 2/3, four-arm parallel, multicenter, single-blind, randomized, controlled clinical trial with 480 patients with a diagnosis of knee osteoarthritis (Kellgren–Lawrence II–IV). Participants were randomized to the three different arms with a 3:1 distribution. Arm 1: autologous bone marrow aspirate concentrate ( $n = 120$ ), CSI ( $n = 40$ ); arm 2: umbilical cord tissue-derived mesenchymal stromal cells ( $n = 120$ ), CSI ( $n = 40$ ); arm 3: stromal vascular fraction ( $n = 120$ ), CSI ( $n = 40$ ). The co-primary endpoints were the visual analog scale pain score and Knee injury and Osteoarthritis Outcome Score pain score at 12 months versus baseline. Analyses of our primary endpoints, with 440 patients, revealed that at 1 year post injection, none of the three orthobiologic injections was superior to another, or to the CSI control. In addition, none of the four groups showed a significant change in magnetic resonance imaging osteoarthritis score compared to baseline. No procedure-related serious adverse events were reported during the study period. In summary, this study shows that at 1 year post injection, there was no superior orthobiologic as compared to CSI for knee osteoarthritis. ClinicalTrials.gov Identifier: [NCT03818737](https://clinicaltrials.gov/ct2/show/study/NCT03818737)

Osteoarthritis (OA) is a degenerative condition that affects millions of patients every year. Although arthritis is considered a disease of abnormal joint mechanics marked by periods of inflammation, the underlying etiology is biochemically mediated leading to destruction

of articular cartilage<sup>1</sup>. OA presents a clinical dilemma in the United States and around the world, affecting more than 54 million Americans according to the 2017 reported assessment by Barbour et al.<sup>2</sup>. The economic burden and cost of care for treatment and lost productivity for

A full list of affiliations appears at the end of the paper. ✉ e-mail: [kmautne@emory.edu](mailto:kmautne@emory.edu); [hicham.drissi@emory.edu](mailto:hicham.drissi@emory.edu)



**Fig. 1 | Consort diagram.** Number randomized to each arm of study with dropouts and reason for dropout included.

54 million Americans caused by OA amounts to US\$60 billion annually in the United States, with recent studies suggesting health care costs alone between US\$5.7 and US\$15 billion<sup>3,4</sup>. Despite advances in diagnosis, medications and injections that control pain and inflammation in the short term, the quest for the development of a disease-modifying OA drug has proven unsuccessful.

The potential of mesenchymal stem cells (MSCs, also referred to as mesenchymal stromal cells) as a treatment for chronic diseases has been investigated in several areas of medicine, including orthopedics. Although still debatable, it is thought that common responses from these cells are inhibiting inflammation, protecting, and supporting chondrocytes, and providing a healthier joint environment<sup>5–8</sup>. In orthopedic practice, autologous cellular injections are widely used with the hopes of reducing pain and improving function. However, a thorough search of the orthopedic literature yielded limited injectable cell data, especially with well-designed randomized controlled trials<sup>8–14</sup>. Thus, a larger clinical trial could add information as to whether cellular treatments, while more expensive than corticosteroids, are more beneficial and if one cell therapy source outperforms another.

In this Article, our objective is to identify the most effective source of cellular injections for knee OA. To accomplish this, three types of cellular preparation including autologous bone marrow aspirate concentrate (BMAC), autologous stromal vascular fraction (SVF) and allogenic human umbilical cord tissue MSCs (UCT) were each compared against the gold-standard corticosteroid injection (CSI). Our co-primary outcome measures are visual analog scale (VAS) and Knee injury and Osteoarthritis Outcome Score (KOOS) pain from baseline to 1 year. We hypothesized that cell therapies would be superior to corticosteroids for treatment of knee OA at 1 year.

## Results

Between March 2019 and June 2021, following prescreening by a research coordinator, 570 patients were screened, 480 of whom

fulfilled eligibility criteria (84%) and were randomized into one of four cohorts and then three subsequent arms (see Fig. 1). All treatments exceeded minimally clinically important difference for both co-primary endpoints and sustained at 1 year post injection procedure. Table 1 provides the participants demographics for the study that were similar between the four treatment groups. Average age of patients in the overall study was 58.3 years with average body mass index (BMI) of 30.8 kg m<sup>-2</sup>. There were 214 (45.1%) males and 261 (54.9%) females who received injections. Although initially planned as a subgroup analysis, racial diversity was too small to perform statistical analysis. The breakdown of race by group was as follows. In the BMAC cohort there were zero Hispanic, 1 American Indian, 4 Asian, zero native Hawaiian, 19 African American, 92 white and 2 of unknown race (for example, multiple races). In the SVF cohort there were 5 Hispanic, 1 American Indian, 3 Asian, zero native Hawaiian, 15 African American, 99 white and 1 of unknown race. In the UCT cohort there were 5 Hispanic, zero American Indian, 4 Asian, zero native Hawaiian, 11 African American, 102 white and 1 of unknown race. In the CSI cohort there were 6 Hispanic, zero American Indian, two Asian, zero native Hawaiian, 12 African American, 104 white and 2 of unknown race.

## Primary outcome

Both primary outcome measures results are shown in Fig. 2. The co-primary-outcome measure of VAS pain score was analyzed as the change from baseline to 12 months. The mean decline from baseline in VAS pain score changed in different ways by treatment group but was not significantly different in overall decline (for example, overall magnitude was same, but trajectory was different). There were no significant differences between groups at month 12 in the change in VAS score from baseline (change,  $-24.3 \pm$  standard error of the mean (s.e.m.) in BMAC,  $-19.4 \pm$  s.e.m. in SVF,  $-20.1 \pm$  s.e.m. in UCT and  $-20.9 \pm$  s.e.m. in CSI; difference versus CSI, BMAC:  $-3.4$ ;  $P = 0.19$ , SVF:

**Table 1 | Demographic and baseline characteristics by treatment group for the intent-to-treat population**

	BMAC n=118	SVF n=119	UCT n=118	CSI n=120	All subjects n=475
Age (years)					
Mean±s.d.	58.6±7.3	58.2±7.3	57.9±8.2	58.3±8.1	58.3±7.7
≥60, n (%)	61 (52%)	56 (47%)	54 (46%)	58 (48%)	229 (48%)
<60, n (%)	57 (48%)	63 (53%)	64 (54%)	62 (52%)	246 (52%)
BMI (kg m <sup>-2</sup> ), n	104	106	115	107	432
Mean±s.d.	30.6±6.0	30.5±6.4	30.9±5.4	31.2±6.2	30.8±6.0
KL grade, n (%)					
Grade 2	31 (26%)	34 (29%)	44 (37%)	34 (28%)	143 (30%)
Grade 3	43 (36%)	52 (44%)	42 (36%)	54 (45%)	191 (40%)
Grade 4	44 (37%)	33 (28%)	32 (27%)	32 (27%)	141 (30%)
Male, n (%)	56 (48%)	56 (47%)	53 (45%)	49 (41%)	214 (45%)
Female, n (%)	62 (53%)	63 (53%)	65 (55%)	71 (59%)	261 (55%)

1.5,  $P = 0.56$ , UCT: 0.8,  $P = 0.76$ ). The analysis of KOOS pain score yielded similar results as there was no significant between-group difference at month 12 in the change in score from baseline (change,  $19.1 \pm$  s.e.m. in BMAC,  $17.2 \pm$  s.e.m. in SVF,  $16.2 \pm$  s.e.m. in UCT and  $17.7 \pm$  s.e.m. in CSI; difference versus CSI, BMAC: 1.4;  $P = 0.49$ , SVF:  $-0.50$ ,  $P = 0.82$ , UCT:  $-1.5$ ,  $P = 0.44$ ). Prima sensitivity analyses were performed using the observed case, the per protocol population and multiple imputation under the assumption of missing not at random. For both the VAS pain score and the KOOS pain score, there was no significant between-group difference at month 12 in the change in score from baseline for any of the sensitivity analyses. Interaction between treatment group and age group (<60 versus ≥60), sex, ethnicity and Kellgren–Lawrence (KL) grade were also analyzed. There was a significant interaction between treatment group and age group ( $P = 0.02$ ) and between treatment group and sex ( $P = 0.01$ ) for VAS pain score. There was no significant interaction for KOOS pain score. In addition, the magnetic resonance imaging (MRI) scores had no significant changes from baseline in any of the four groups (BMAC 0.53, SVF  $-0.40$ , UCT  $-0.26$  and CSI 0.30) compared to their baseline scores or compared to the CSI group (BMAC 0.23, SVF  $-0.69$  and UCT  $-0.55$ ). See Fig. 3 for description of MRI scoring system.

### Secondary outcome

In addition to our primary outcome measures we also analyzed EQ-5D and PROMIS-29 between cohorts and CSI. For EQ-5D, the treatment by time interaction was not significant ( $P = 0.26$ ), suggesting EQ-5D in the four treatment groups changed in similar ways (similar temporal patterns for the four treatment groups). Since the interaction between treatment and time is not significant, we would not expect to see specific ‘change versus change’ differences. Similarly for PROMIS-29, we assessed all domains by a treatment by time interaction and there was no significance for the following subdomains: PROMIS-29 Anxiety ( $P = 0.78$ ), Depression ( $P = 0.06$ ), Fatigue ( $P = 0.56$ ), Pain ( $P = 0.39$ ), Physical Function ( $P = 0.048$ ), Sleep ( $P = 0.91$ ) and Social Rules and Activities ( $P = 0.82$ ). It should be noted that the PROMIS-29 Physical Function was statistically significant, suggesting the physical function PROMIS-29 domain T-score in the four treatment groups changed in different ways (different temporal patterns for the four treatment groups). However no clear clinically important difference in the temporal pattern was apparent between the four treatment groups. The full details for these secondary outcomes are located in Supplementary Material 1.

### Exploratory outcomes

Bedside testing of total nucleated cells injected and viability for each cellular group was analyzed. In addition, 71 BMAC, 16 SVF and 8 UCT-MSc samples at the time of publication were subjected to single-cell RNA sequencing to reveal differences and similarities in the cellular components of each product via cell clustering analyses visualized in two dimensions using Uniform Manifold Approximation and Projection. Transcriptomic analyses at the single-cell resolution revealed that both autologous cell sources exhibited distinct cell subpopulations with some similarities in a subset of hematopoietic lineage-derived cells. Conversely, the UCT mesenchymal population, although exhibiting a defined clustering pattern, showed a uniform MSC phenotype.

### Safety


There were no procedure-related serious adverse events (AEs) reported, which includes any allergic reactions or symptomatic infections seen in any treated patient. However, there were multiple related AEs reported that have been subdivided. The following related AEs demonstrated significance between cohorts: joint swelling (CSI 7.4% versus UCT 24.1%,  $P = 0.01$ ), post-procedural contusion (SVF 38.6% versus BMAC 12.2% versus UCT/CSI 0%,  $P < 0.0001$ ), post-procedural hematoma (BMAC 2.9% versus SVF 12.4%,  $P = 0.02$ ). For a list of the most common AEs by study arm and by study group, see Tables 2 and 3.

### Discussion

This study demonstrated no superiority of any cell therapy over corticosteroids at 1 year when VAS and KOOS were compared. In addition, other measures including EQ-5D and PROMIS also showed no superiority among cellular therapies over CSI. As such, the primary hypothesis was rejected. Given the complexity of the study, patients and cells involved, no direct knowledge was attained from our primary analysis about the personalization of cellular injections for patients.

The question of the most beneficial cellular treatment, and the assumption of superiority over CSI, has been debated for some time. However, large randomized clinical trials have been difficult to perform. Previously, the discussion over which source of cells are superior has been predominantly based on laboratory data analyzing MSCs, colony-forming units or other secretory factors. This type of approach is complicated by the large amount of heterogeneity among autologous and allogeneic products based on the donors who supply these cells. Based on in vitro analysis, the consensus is that birth tissue products will produce the higher number of true MSCs, but questions over the manufacturing, processing and efficacy of such treatments have been raised as most of the commercial products that have been available for use show no live MSCs<sup>15,16</sup>. However, autologous products have been shown to be extremely safe as same-day procedures and have consistently high cell viability. Our study has corroborated these findings and showed safety and tolerability of all the cellular therapies used. These cellular injection preparations, however, do not have large numbers of MSCs, and the therapeutic mechanism of action and overall efficacy have been called into question. Human clinical research has not clearly demonstrated success of these treatments, even with the most rigorous randomized control trial, which demonstrated equal improvement in pain with bilateral knee OA with BMAC injected to one knee and a saline injection in the other knee<sup>9</sup>. There have been, however, an abundance of case reports and case series in the literature that have shown favorable success and several meta-analyses that support the use of these products<sup>17,18</sup>.

A benefit of this large study was the evaluation of the safety of these procedures. Since this was a US Food and Drug Administration (FDA)-approved study, every adverse reaction, from pain and swelling in the joint to hospitalizations for illnesses unrelated to the study intervention, was recorded in real time. There were no study-related serious AEs or symptomatic knee infections noted in any of the treatment



**Fig. 2 | Primary outcome measures over time. a,b.** Results of primary outcome change from baseline for VAS pain (a) and change from baseline for KOOS pain score (b) by treatment group and months since randomization. The time trend

lines are the model-based means and 95% CIs. The vertical lines are the 95% CIs. Sample sizes for each treatment group at each time point are reported below each figure.

groups at any point during follow-up. The study-related AEs of procedural and post-procedural pain were highest in the SVF cohort followed by BMAC, and there were very few related AEs, none of which was severe. Almost all of the reported AEs recovered by the 1-week follow-up visit. This is consistent with previous reports of two large case series: one by Centeno et al in 2016 (ref. 19), the other by Hernigou in 2013 (ref. 20). These studies both examined BMAC procedures and AEs, and found, like us, that procedural pain or injection site pain were the only significant findings. Our study confirms an exceptional safety profile of these percutaneous procedures.

As none of the treatment groups was superior to another, it was deemed important to subgroup patients on the basis of their grade of arthritis. The use of KL scoring preinjection was used to classify patients accordingly. Despite having three types, II, III and IV, the KL grade was not a reliable predictor of success. The literature often points to a direct correlation between KL grading and specific product efficacy in small cohorts<sup>21,22</sup>. We speculate that the lack of differences among the KL grades may be due to the relative function of those with worse KL grades at the beginning of the trial or the large heterogeneity in age and sex that we recruited on the basis of our wide inclusion criteria aimed at decreasing bias. In no treatment group did we see any

notable improvement in MRI scores when comparing corticosteroids to cellular injections. Moreover, the steroid group's MRI scores did not significantly worsen over the 1-year mark and the cellular groups did not improve over that period. There were, however, certain MRIs that showed improvement over the 1-year period as evidenced by their MRI scoring. These changes will be further investigated in subsequent papers and with our extension study that will further characterize MRI changes 2 and 3 years post treatment. It should be noted that OA is a slow progressive process, and it is possible that a 1-year timeline was too short for this secondary measure.

Significant measures were taken to eliminate potential bias in our study, including blinding of authors to original data before final analysis. The primary analyses and the sensitivity analyses allowed us to evaluate all scenarios including subject loss, as we designed the study as intent to treat. However, selection bias may arise from differences between participants who selected to start the trial and those who did not. With interventions for knee OA, there is a well-described placebo effect that we must acknowledge. When trying to account for this placebo effect, one must look at studies where saline was used. It is debatable as to whether saline is a true control or has some therapeutic effect by diluting and washing away inflammatory mediators as well

Features		Score	Criteria	Locations and maximum possible score						Maximum score
				Pat	Troch	LFC	LTP	MFC	MTP	
Cartilage loss	Severity	0, 1, 2	None, partial, full	2	2	2	2	2	2	12
	Extent	0, 1, 2	None, <50%, ≥50%	2	2	2	2	2	2	12
BME or Cyst	Severity	0, 1, 2	None, moderate, severe	2	2	2	2	2	2	12
Osteophytes	Size/extent	0, 1	Absent, present	1	1	1	1	1	1	6
				aLM	bLM	pLM	aMM	bMM	pMM	
Menisus	Severity	0, 1, 2	Normal, degenerated, tear	2	2	2	2	2	2	12
Menisus extrusion	Severity	0, 1	<2 mm, ≥2 mm		1				1	2
Ligaments	Severity	0, 1, 2	Normal, degenerated, tear	2	2	2	2			8
				ACL	PCL	MCL	LCL			
Synovitis/effusion	Severity	0, 1, 2	None, moderate, severe	2						2
Fat pad alt SI	Severity	0, 1		1		1		1		3
				Prefemoral	Suprapatellar	Hoffa's				
									Maximum possible total score	69

**Fig. 3 | MRI scoring system used. The MRI is graded from 0 to 69, with the higher number representing more severe grades of OA.** Features: BME (bone marrow edema) or Cyst, fat pad alt SI, fat pad signal intensity alteration. Location: Pat, patella; Troch, trochlea; LFC, lateral femoral condyle; LTP, lateral tibial plateau; MFC, medial femoral condyle; MTP, medial tibial plateau; aLM, anterior horn of lateral meniscus; bLM, body of lateral meniscus; pLM, posterior horn of lateral meniscus; aMM, anterior horn of medial meniscus; bMM, body of Medial

Meniscus, pMM, posterior horn of medial meniscus; ACL, anterior cruciate ligament; PCL, posterior cruciate ligament; MCL, medial collateral ligament; LCL, lateral collateral ligament. Prefemoral, pre-femoral fat pad; Suprapatellar, suprapatellar fat pad; Hoffa's, Hoffa's fat pad. There was a total of 40 separate scores, adding up to the highest possible score of 69, representing the worst possible grade (that is, worst knee health). The MRI is graded from 0 to 69, with the higher number representing more severe grades of OA.

**Table 2 | Summary of AEs by treatment group according to MedDRA system**

MedDRA system organ class (preferred term)	BMAC (N=107)		SVF (N=109)		UCT (N=116)		CSI (N=108)		All subjects (N=440)	
	n (%)	95% CI	n (%)	95% CI	n (%)	95% CI	n (%)	95% CI	n (%)	95% CI
Musculoskeletal connective tissue disorders										
Arthralgia	27 (25.2)	17.3, 34.6	25 (22.9)	15.4, 32.0	30 (25.9)	18.2, 34.8	28 (25.9)	18.0, 35.2	110 (25.0)	21.0, 29.3
Joint stiffness	13 (12.1)	6.6, 19.9	6 (5.5)	2.0, 11.6	8 (6.9)	3.0, 13.1	8 (7.4)	3.3, 14.1	35 (8.0)	5.6, 10.9
Joint swelling	19 (17.8)	11.0, 26.3	16 (14.7)	8.6, 22.7	28 (24.1)	16.7, 33.0	8 (7.4)	3.3, 14.1	71 (16.1)	12.8, 19.9

The safety population is defined as the 440 subjects who received study treatment. The AEs are those with an incidence of at least 5%. MedDRA denotes Medical Dictionary for Regulatory Activities, version 21.1. 95% CIs that do not overlap are statistically significant.

as aspiration of joint fluid, which occurs before any intervention. It is unclear whether different solutions and cellular therapies have this same dilution effect or if there is a reactionary byproduct from cellular injectates over saline. This placebo effect has been studied extensively in this area, with overall data suggesting there could be upwards of 50% response rate as well as up to 6 months improvement in pain and possibly even longer improvement in function<sup>23,24</sup>. It is unclear if there was a placebo effect given the fact that patients were blinded to their treatment and underwent sham procedures (for example, they may have assumed it worked because they got 'stem cells' or did not work because they got 'steroids'). There were clearly some patients who did

not respond to cellular or steroid therapies, and it is unclear whether these patients were subject to a placebo type effect<sup>25</sup>.

Although no study is perfect, our study identified that at 1 year post injection there was no cellular therapy that was more effective than CSI for knee OA. In addition, the study demonstrates in a large cohort the relative safety of these cellular procedures without evidence of severe AEs. It should be noted that a multiarm clinical trial evaluating the safety and efficacy of cellular biologics as compared to corticosteroid is exceedingly complex with multiple viewpoints and perceptions. A large team of scientists including expert opinion, critiques and requirements from the FDA shaped this study into its



**Table 3 | Summary of procedure related AEs by study arm**

MedDRA system organ class (preferred term)	Arm 1 (BMAC bone marrow harvest) (N=139)		Arm 2 (SVF fat harvest) (N=145)		Arm 3 (UCT CSI no harvest) (N=156)	
	n (%)	95% CI	n (%)	95% CI	n (%)	95% CI
Injury, poisoning and procedural complications						
Post-procedural contusion	17 (12.2)	7.3, 18.9	56 (38.6)	30.7, 47.1	0	0.0, 2.3
Post-procedural hematoma	4 (2.9)	0.8, 7.2	18 (12.4)	7.5, 18.9	0	0.0, 2.3
Procedural pain	41 (29.5)	22.1, 37.8	49 (33.8)	26.2, 42.1	1 (0.6)	0.0, 3.5

The safety population is defined as the 440 subjects who received study treatment. The AEs are those with an incidence of at least 5%. MedDRA denotes Medical Dictionary for Regulatory Activities, version 21.1. 95% CIs that do not overlap are statistically significant.

current form. Additional conclusions and responder analyses will be discussed more in future papers.

### Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02632-w>.

### References

- Lee, A. S. et al. A current review of molecular mechanisms regarding osteoarthritis and pain. *Gene* **527**, 440–447 (2013).
- Barbour, K. E., Helmick, C. G., Boring, M. & Brady, T. J. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2013–2015. *Morb. Mortal. Wkly Rep.* **66**, 246–253 (2017).
- Bedenbaugh, A. V., Bonafede, M., Marchlewicz, E. H., Lee, V. & Tambiah, J. Real-world health care resource utilization and costs among US patients with knee osteoarthritis compared with controls. *Clinicoecon. Outcomes Res.* **13**, 421–435 (2021).
- Buckwalter, J. A., Saltzman, C., & Brown, T. The impact of osteoarthritis: implications for research. *Clin. Orthop. Relat. Res.* <https://doi.org/10.1097/01.blo.0000143938.30681.9d> (2004).
- Rodriguez-Fuentes, D. E. et al. Mesenchymal stem cells current clinical applications: a systematic review. *Arch. Med. Res.* **52**, 93–101 (2021).
- Molnar, V. et al. Mesenchymal stem cell mechanisms of action and clinical effects in osteoarthritis: a narrative review. *Genes* **13**, 949 (2022).
- Caplan, A. I. Why are MSCs therapeutic? New data: new insight. *J. Pathol.* **217**, 318–324 (2009).
- Kim, K. I., Kim, M. S. & Kim, J. H. Intra-articular injection of autologous adipose-derived stem cells or stromal vascular fractions: are they effective for patients with knee osteoarthritis? A systematic review with meta-analysis of randomized controlled trials. *Am. J. Sports Med* **51**, 837–48. (2023).
- Shapiro, S. A., Kazmerchak, S. E., Heckman, M. G., Zubair, A. C. & O'Connor, M. I. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. *Am. J. Sports Med.* <https://doi.org/10.1177/0363546516662455> (2016).
- Di Matteo, B. et al. Minimally manipulated mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review of clinical evidence. *Stem Cells Int.* **2019**, 1–14 (2019).
- Yubo, M. et al. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis. *PLoS ONE* **12**, e0175449-e (2017).
- McIntyre, J. A., Jones, I. A., Han, B. & Vangsnes, C. T. Intra-articular mesenchymal stem cell therapy for the human joint: a systematic review. *Am. J. Sports Med.* **46**, 3550–3563 (2018).
- Garza, J. R. et al. Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: a double-blinded prospective randomized controlled clinical trial. *Am. J. Sports Med.* **48**, 588–98. (2020).
- Pintore, A. et al. Intra-articular injection of bone marrow aspirate concentrate (BMAC) or adipose-derived stem cells (ADSCs) for knee osteoarthritis: a prospective comparative clinical trial. *J. Orthop. Surg. Res* **18**, 350 (2023).
- Beckett, L. et al. Proteomic analysis and cell viability of nine amnion, chorion, umbilical cord, and amniotic fluid-derived products. *Cartilage* **13**, 495S–507S (2021).
- Panero, A. J., Hirahara, A. M., Andersen, W. J., Rothenberg, J. & Fierro, F. Are amniotic fluid products stem cell therapies? A study of amniotic fluid preparations for mesenchymal stem cells with bone marrow comparison. *Am. J. Sports Med* **47**, 1230–1235 (2019).
- Song, Y. et al. Mesenchymal stem cells in knee osteoarthritis treatment: a systematic review and meta-analysis. *J. Orthop. Transl.* **24**, 121–130 (2020).
- Ma, W. et al. Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis: a systematic review and meta-analysis. *Medicine* **99**, e23343 (2020).
- Centeno, C. J. et al. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. *Int. Orthop.* **40**, 1755–1765 (2016).
- Hernigou, P. et al. Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate. *J. Bone Jt Surg. Am.* **95**, 2215–2221 (2013).
- Kim, J. D. et al. Clinical outcome of autologous bone marrow aspirates concentrate (BMAC) injection in degenerative arthritis of the knee. *Eur. J. Orthop. Surg. Traumatol.* **24**, 1505–1511 (2014).
- Mautner, K., Bowers, R., Easley, K., Fausel, Z. & Robinson, R. Functional outcomes following microfragmented adipose tissue versus bone marrow aspirate concentrate injections for symptomatic knee osteoarthritis. *Stem Cells Transl. Med* **8**, 1149–56 (2019).
- Fazeli, M. S., McIntyre, L., Huang, Y. & Chevalier, X. Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence. *Ther. Adv. Musculoskelet. Dis.* **14**, 1759720X211066689 (2022).
- Previtali, D. et al. The long-lasting effects of 'placebo injections' in knee osteoarthritis: a meta-analysis. *Cartilage* **13**, 185S–196SS (2021).
- Bannuru, R. R. et al. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. *Ann. Intern. Med.* **163**, 365–372 (2015).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this

article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

---

<sup>1</sup>Department of Orthopaedics, Emory University, Atlanta, GA, USA. <sup>2</sup>Department of Radiology, University of California, Davis, La Jolla, CA, USA. <sup>3</sup>Sanford Health, Sioux Falls, SD, USA. <sup>4</sup>Duke Sports Medicine, Durham, NC, USA. <sup>5</sup>Marcus Center for Therapeutic Cell Characterization and Manufacturing, Georgia Institute of Technology, Atlanta, GA, USA. <sup>6</sup>Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA. <sup>7</sup>Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, GA, USA. <sup>8</sup>Andrews Institute, Gulf Breeze, AL, USA. <sup>9</sup>Marcus Center for Therapeutic Cures, Duke University, Durham, NC, USA. <sup>10</sup>Sanford Health, Fargo, ND, USA. <sup>11</sup>Biomedical Engineering, Vanderbilt University, Nashville, TN, USA. <sup>12</sup>These authors contributed equally: Ken Mautner, Michael Gottschalk. ✉e-mail: [kmautne@emory.edu](mailto:kmautne@emory.edu); [hicham.drissi@emory.edu](mailto:hicham.drissi@emory.edu)



## Methods

### Study design and participants

This was a multicenter single-blinded study performed in accordance with guidelines and oversight from the FDA, and under the management of a contracted research organization. Study approval was obtained from the Western Institutional Review Board and by Duke and Emory University's institutional review board. In accordance with the FDA, an investigational new drug application was filed, #18414, which referenced investigator device exemption #17894. The study was also registered with ClinicalTrials.gov, [NCT03818737](https://clinicaltrials.gov/ct2/show/study/NCT03818737). Data availability at this time is available by request to the corresponding author(s).

A total of 570 patients were screened to identify 480 eligible patients who were randomized at five clinical sites in five different states within the United States. The five clinical sites included clinics from Emory, Sanford (two sites), Andrews Institute, and Duke. For a consort diagram of participants entered in study, see Fig. 1. Participants were randomized to a four-cohort parallel-design study. To allow for blinding, participants were further subdivided to three arms given the need to 'sham' harvest cells from subjects in the SVF and BMAC arm, but not in the UCT/CSI arm: arm 1—autologous bone marrow concentrate (BMAC) ( $n = 120$ ), corticosteroid (CSI) ( $n = 40$ ); arm 2—SVF ( $n = 120$ ), CSI ( $n = 40$ ); arm 3—umbilical cord tissue (UCT) ( $n = 120$ ), CSI ( $n = 40$ ). The control cohort of CSI was then aggregated to allow a 1:1:1 comparison for analysis. Subjects were enrolled if they were between 40 and 70 years of age and carried a diagnosis of knee OA as determined by radiographs within 3 months of their clinical visit. A full list of eligibility criteria is provided on ClinicalTrials.gov, [NCT03818737](https://clinicaltrials.gov/ct2/show/study/NCT03818737). A total of five samples did not meet release criteria, including one BMAC and four SVF. This was secondary to failure of endotoxin testing and not formal cell count. Additionally, the following failed to complete the study. In the BMAC cohort, a total of 12 subjects did not complete the study, with 1 related to release criteria as above, 10 related to subject withdrawal and 1 lost to follow-up. In the SVF cohort, a total of 12 subjects did not complete the study, with 1 due to investigator withdrawal, 4 related to release criteria as above, 6 related to subject withdrawal and 1 due to screen fail. In the UCT cohort, a total of 13 subjects did not complete the study, with 2 due to investigator withdrawal, 10 related to subject withdrawal and 1 lost to follow-up. Lastly, in the CSI cohort, a total of 11 subjects did not complete the study, with 1 due to investigator decision, 6 related to subject withdrawal and 4 lost to follow-up. Patients returned to clinic for MRI to assess cartilage and joint health at baseline, 6 months and 1 year. They were compensated US\$50 for each MRI that was performed.

### Randomization and masking

Subjects were stratified by clinical center, and after obtaining informed consent and verifying eligibility criteria were met, subjects were randomized. Treatment assignments were stratified by clinical center and generated using a pseudo-random number generator with randomly permuted blocks. These assignments were stored in the Medidata Rave cloud-based data management system developed by the contracted research organization. All subjects underwent the harvesting procedure per their assigned study arm, then per the randomization scheme they were blinded to the actual treatment received (for example, SVF versus CSI, BMAC versus CSI, or cells versus CSI). As a single-blinded study, the site principal investigators were not required to be blinded. However, subjects were blinded to their injection. The blinding was implemented by limiting visualization of the syringe contents with opaque covering in addition to performing sham BMAC and SVF harvests in patients within certain cohorts.

### Procedures

The cellular harvesting, final product preparation, injection procedures and CSI were standardized across the five study sites. This was done through training courses before study initiation as well as

subsequent monitoring by the lead site. Of note, the BMAC and SVF were fresh autologous products while the UCT were cryopreserved, purified MSCs manufactured from donated allogeneic umbilical cord tissue in a cGMP (current Good Manufacturing Practice) facility. Supplementary Material 1 details the contents of each preparation that was injected.

All procedures were done in an outpatient clinic setting with another clean room used for point-of-care laboratory testing. No cGMP facility was used for the actual treatment portion of this study. The subject was positioned supine on an examination table with foam roller/bolster under knee. The injectate was prepared by the research team with opaque tape wrapped around the 10-ml syringe to maintain the blinding. If an effusion was present based on clinical and ultrasound examination, 2 ml of ropivacaine 0.2% was injected between the skin and down to the joint capsule. Following this, an 18-gauge needle was used to aspirate any joint fluid via a superior lateral approach under direct ultrasound guidance. Following joint aspiration (if performed), the solution of either corticosteroids, BMAC, SVF or UCT was injected under ultrasound guidance. Following the injection, the knee was passively moved from extension to flexion three to four times to help spread the injectate and patients were instructed to remain supine for 10 min.

All final cellular products were tested in the clinic for total nucleated cell count, cell viability and endotoxin levels to determine if release criteria were met before injection. These tests were performed using a Nexcelom Auto 2000 device for cell counting and cell viability and the Charles River Endosafe Nexgen PTS for endotoxin testing. A 1-ml aliquot of each cellular product was separated from the final injection preparation for the release criteria testing and FDA requirements. If the final product did not meet the required release criteria depicted in Table 1, the subject did not receive the injection. This was seen in one BMAC patient and four SVF patients. In addition to bedside testing, 14-day sterility testing was performed post administration per FDA requirements. In an effort to standardize the injectate and per FDA guidance, cutoffs and cellular numbers were derived from a group of subject matter experts.

Cellular diversity in BMAC and SVF samples and cellular heterogeneity in UCT-MSC samples were evaluated by single-cell RNA sequencing. The single-cell RNA sequencing libraries were prepared with 10x Genomics Chromium platform using 3' V3.1 kit. The sequencing was done on Illumina Novaseq 6000 platform with an S4 kit. We used a modified SEURAT pipeline to analyze the samples<sup>26</sup>. We then applied filters to include cells that had more than 800 unique molecular identifiers, more than 500 expressed genes and mitochondria percentage less than 20%.

### Outcomes

The primary analyses of the data were performed according to subjects' original treatment assignment (that is, intention-to-treat analyses) regardless of their compliance and the inclusion of all data from all subjects randomized in the final analysis. The two co-primary efficacy endpoints in this intent-to-treat, parallel-group trial were VAS and KOOS pain score at 12-month visit from baseline.

KOOS is a self-reported outcome measure assessing the patient's opinion about the health, symptoms and functionality of their knee. It is a 42-item questionnaire, including five subscales: symptoms, pain, activities of daily living, sports/recreation and quality of life. The maximum score a patient can achieve is 100, and the minimum score is zero, indicating severe knee problems. KOOS has been verified in assessing patients of various age populations, ranging from young to elderly adults<sup>27</sup>.

The VAS is a single-item measure that most commonly consists of a 100-mm horizontal line anchored with two opposite labels; patients mark a score on the scale using a vertical line<sup>28</sup>. Magnetic resonance images were evaluated by a musculoskeletal radiologist according to

a semi-quantitative method for whole-knee analysis in the setting of OA. Our methodology, adopted from past work (that is, WOMBS (1) and BLOKS (2) grading schemes) evaluated severity and/or extent of cartilage loss, bone marrow edema (BME) or cyst, osteophytes, meniscus pathology and extrusion, ligament pathology, synovitis, and fat pad inflammation<sup>29,30</sup>. Both WOMBS and BLOKS were utilized for this study. T2 mapping is a technique to determine intrinsic spin-lattice relaxation times of biological tissues and has been studied extensively in the knee to assess cartilage and meniscus degeneration. For this project, we utilized spin echo T2 mapping technique, where four to eight images with echo times ranging from -10 ms to -80 ms were obtained in weight-bearing regions of the medial and lateral compartments. For the magnetic resonance scoring system that was used, see Fig. 3.

### Statistical analysis

Power and sample size considerations for the trial are found in Supplementary Material 1. For primary endpoint analyses, missing data for VAS pain scores and KOOS pain scores were imputed using multiple imputation under the missing at random assumption. Independent imputations were performed for VAS pain scores and KOOS pain scores. Absolute change from baseline in VAS pain score and KOOS pain score were derived from the corresponding imputed scores. Sensitivity analyses for the primary endpoints were performed using the observed case, the per protocol population and multiple imputation based on a pattern-mixture model under the assumption of missing not at random (all found in Supplementary Material 1.).

A repeated-measures analysis of change of VAS pain score (and change of KOOS pain score) was performed with a means model via the SAS MIXED Procedure (version 9.4; SAS Institute, Cary, NC), providing separate estimates of the means by treatment group (BMAC, SVF, UCT and CSI) time on study (1, 3, 6, 9 and 12 months on study) and treatment group. The models included treatment arm, time on study, the statistical interaction between treatment arm and time on study and study center as fixed effects. A compound-symmetric variance-covariance form in repeated measurements was assumed, and robust estimates of the standard errors of parameters were used to perform statistical tests and construct 95% confidence intervals (CIs)<sup>31</sup>. The model-based means are unbiased with unbalanced and missing data, if the missing data are non-informative (missing at random). The main effect test for treatment at the 12-month visit was used as the primary hypothesis test to compare the treatment arms. The primary study results from this model were the mean change score and 95% CI for each of the four treatment cohorts and the treatment mean differences and 95% CIs. Pairwise treatment comparisons on efficacy score change were performed. The primary comparisons were each cellular treatment against control group. A Hochberg adjustment method was used to maintain the overall  $\alpha$  level, which ordered the  $P$  value from high to low and compared the largest  $P$  value to 0.05, the middle  $P$  value to 0.05/2 and the smallest  $P$  value to 0.05/3 (ref. 32). Specific statistical tests were done within the framework of the mixed effects linear model. All statistical tests were two-sided. Secondary efficacy endpoint analyses (all VAS, KOOS and EQ-5D 3L scores) were conducted using an observed case analysis using the same plan described for the change scores. No interim analyses for efficacy were performed for this study.

The heterogeneity of treatment effects across levels of a baseline variable was investigated using a statistical test for interaction. A prespecified subgroup analysis is one that is planned and documented before examination of the data. Planned subgroup analyses were performed to examine the impact of treatment on the primary outcomes in the prespecified subgroups (that is, sex, ethnicity and KL grade). Effect of treatment in subgroups was determined by including the interaction between treatment and subgroup in the repeated-measures model described above using an observed case analysis. Additional secondary and exploratory outcome measures included change in MRI cartilage and joint health from baseline to 1 year, analysis of AEs and

complications between groups, as well as in-depth cellular analysis of each injectate.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Upon discussion with our study leadership, we plan to make data available by request only initially, and will make publicly available following completion of additional manuscripts that are still to be submitted. In addition, significant portions of our data are available in our Supplementary Information. Submit data requests to corresponding authors K.M. and H.D.

### References

26. Phipson, B. et al. propeller: testing for differences in cell type proportions in single cell data. *Bioinformatics* **38**, 4720–4726 (2022).
27. Roos, E. M. & Lohmander, L. S. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. *Health Qual. Life Outcomes* **1**, 64 (2003).
28. Boonstra, A. M., Schiphorst Preuper, H. R., Reneman, M. F., Posthumus, J. B. & Stewart, R. E. Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain. *Int. J. Rehabil. Res.* **31**, 165–169 (2008).
29. Wang, X. Z. et al. Study on the diagnostic value of whole-organ magnetic resonance imaging score (WORMS) in knee osteoarthritis. *Zhongguo Gu Shang* **25**, 364–368 (2012).
30. Hunter, D. J. et al. The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). *Ann. Rheum. Dis.* **67**, 206–211 (2008).
31. Diggle, P. J., Liang, K. Y. & Zeger, S. L. *Analysis of longitudinal data*. 68–69 (Clarendon Press, 1994).
32. Chen, S. Y., Feng, Z. & Yi, X. A general introduction to adjustment for multiple comparisons. *J. Thorac. Dis.* **9**, 1725–1729 (2017).

### Acknowledgements

The MILES study leadership wishes to acknowledge and thank the following study staff for their hard work, perseverance and dedication: S. Hampton, I. Vernon, L. Veda, K. Atkins, A. Tuchscherer, J. Sharp, R. Walker, B. Piatt, E. Pennington, D. Pearce, H. Lawrence Nguyen, L. Bahntge, S. Lafta, B. Kompelien, D. Herman, S. Finley, C. Rhodes, E. Reinke, S. Dahl, J. H. Chin, C.-H. Chan and E. Wagner. We also wish to acknowledge and gratefully thank the sponsor of this important study, the Marcus Foundation. The sponsors had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

### Author contributions

K.M.: site Principal Investigator (PI)—literature search conceptualization, study design, investigation, writing original draft and data interpretation. M.G.: Director of Clinical Research: conceptualization, study design, writing original draft and data interpretation. S.B.: study PI and sponsor to FDA—conceptualization, funding acquisition, study design, resources, data interpretation, review and editing. A.A.: project administration, review and editing, study design and data collection. W.C.B.: study design, data collection and data interpretation. L.B.: Director of Clinical Research Sanford—study design, review and editing. B.B.: site PI—review and editing, study design, data collection and investigation. P.C.: data generation, data interpretation, review and editing, and formal analysis. C.B.C.: study design, data collection and data interpretation. K.A.E.: study design, data analysis, data interpretation, writing original draft, review

and editing, and methodology. G.G.: data interpretation, review and editing, and formal analysis. J.H.: site PI—review and editing, study design, data collection and investigation. K.J.: Sanford—study design, project administration and writing (figures and tables). L.K.: study design, data interpretation and conceptualization. C.K.: site PI at Sioux Falls—review and editing, study design, data collection and investigation. J.K.: study design, review and editing, data interpretation, and oversight of laboratory manufacturing human cord tissue MSCs for the clinical trial. R.A.M.: data collection as co-PI. B.N.: site PI at Fargo—review and editing, study design, data collection and investigation. K.R.: study design, review and editing, data interpretation and conceptualization. V.V.: site PI at Sioux Falls—data collection and investigation. C.Y.: study design, data interpretation and conceptualization. H.D.: conceptualization, funding acquisition, study design, resources, data interpretation, and review and editing.

### Competing interests

Several of our authors work for Sanford Health. Sanford Health has a financial interest in InGeneron, Inc., the SVF company used in this study. None of the individual physician has a financial conflict or

relationship with InGeneron, Inc. K.M. is a consultant for Lipogems, which is a micronized fat company, not used in this current study. P.C., G.G., L.K., J.K., K.R. and C.Y. all receive separate grant/salary support from the Marcus Foundation, who funded this study.

### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02632-w>.

**Correspondence and requests for materials** should be addressed to Ken Mautner or Hicham Drissi.

**Peer review information** *Nature Medicine* thanks Susanne Grässel and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Jerome Staal, in collaboration with the *Nature Medicine* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

For data collection, Medidata Rave 2022.1.0 was the version in use at the time of the database lock. We used Rave Coder 2022.1.0 as the tool for medical coding, Rave Medical Imaging v2021.3.3 to collect the MRI data and Rave RTSM 2022.2.0 for randomization.

Data analysis

Statistical analysis will be performed using SAS® (version 9.4).

Handling of Missing Data

For primary analyses, missing data for VAS pain scores (over 1 Month) and KOOS pain scores will be imputed using Multiple Imputation (MI) under the Missing At Random (MAR) assumption. The following steps will be followed:

1. For VAS pain scores (over 1 Month) and KOOS pain scores, the missingness pattern in the data will be evaluated. If the pattern is not monotone, the MCMC method of SAS PROC MI will be used to make it monotone. The single chain method will be used, with 200 burn-in iterations and 100 iterations between imputations. The minimum values for imputed variables will be set to 0, in order to force PROC MI to redraw another value for imputation when an intended imputed value is less than the 0. For VAS pain scores (over 1 Month) and KOOS pain scores, the maximum value for imputed variables will be set to 100, in order to force PROC MI to redraw another value for imputation when an intended imputed value is greater than the 100. For VAS pain scores (over 1 Month) only, imputed values will be rounded to the nearest integer. The seed number will be set to 202394 and fifty (50) imputations will be created.

2. SAS PROC MI will be used for imputing missing values of data with monotone missing pattern. If the MCMC method of step 1 was previously employed, one imputation will be made using each of the fifty (50) MCMC-imputed datasets. If the MCMC method of step 1 was not previously employed, fifty (50) imputations will be created assuming the data are Missing At Random. The seed number will be set to 202394.

These imputations will use the following model:

For VAS pain scores (over 1 Month) and KOOS pain scores, a linear regression model will be used with covariates for treatment and non-missing VAS pain score (over 1 Month) and KOOS pain score from earlier scheduled time points including baseline.

3. The imputed datasets will be analyzed as specified in the primary efficacy analyses section.

4. The resulting analysis on the imputed datasets will then be combined to produce a single set of statistics as follows:

For VAS pain scores (over 1 Month) and KOOS pain scores, results from the MMRM analysis will be combined using the SAS PROC MIANALYZE.

#### Primary Efficacy Analyses

Using SAS Proc Mixed procedure, a mixed model will be fit on each efficacy variable. The models will include site, treatment arm, time on study (baseline and 1,3,6,9, and 12 months on study), and treatment arm by time interaction as fixed effects. A compound-symmetric variance-covariance form in repeated measurements will be assumed and robust estimates of the standard errors of parameters will be used to perform statistical tests and construct 95% confidence intervals

#### Analysis of MRI data

Absolute change in MRI Score from baseline to month 12 will be analyzed on MRI endpoints using an ANCOVA with site, treatment arm and baseline MRI Score as fixed effects; the p-values for the treatment comparison, estimates of the treatment difference and the 95% confidence interval of the difference will be generated from the ANCOVA model. SAS Proc Mixed will be used to analyze MRI data.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

*Provide your data availability statement here.*

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender

This study included both males and females that met the inclusion/exclusion criteria. Sex of subject was self reported with no data collected regarding gender preference. There was a significant interaction between treatment group sex (P=0.01) for VAS pain score over 1 Month.

Population characteristics

#### ANALYSIS POPULATIONS

##### 5.1 Intent-to-treat Population

The ITT population is defined as all subjects who signed the informed consent and were randomized. The ITT population will be used for all efficacy analysis as a primary analysis set with treatment assignment based on randomization.

##### 5.2 Safety Population

The Safety population is defined as all subjects who have received study treatment. The safety population will be used for all safety analyses with treatment actually received.

##### 5.3 Per Protocol Population

The Per-Protocol Population (PP) includes subjects in the ITT population without any major protocol deviations. A major protocol deviation is a deviation that may significantly impact the completeness, accuracy, and/or reliability of the trial data; that may significantly affect a subject's rights, safety, or well-being (ICH E3 R1 Guidelines 2013).

At the primary efficacy analysis, protocol violators resulting in exclusion from the PP population will be identified by the sponsor and documented prior to the database freeze.

Recruitment

Eligible subjects were recruited at five participating sites primarily from the patients already being seen for knee osteoarthritis in those clinics. Subjects also contacted the participating sites from contact information provided in the clinicaltrials.gov study description, from IRB approved recruitment materials, and by word of mouth from subjects already in the study. There is no potential for self-selection bias or other biases that would impact the results.

Ethics oversight

The study protocol was approved by Western Institutional Review Board (WIRB), as well as by local site institutional IRBs as required by those sites. Emory University required local IRB approval due to the sponsor to the FDA being a faculty member, Dr. Scott Boden. Duke University required local IRB approval as well.

Note that full information on the approval of the study protocol must also be provided in the manuscript.



## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<p>The total estimated sample size for the proposed intention-to treat, parallel-group, multicenter, randomized, controlled trial is 480 subjects. The primary endpoints are Visual Analog Scale (VAS) pain score and the pain subsection of Knee Injury and Osteoarthritis Outcomes (KOOS). The sample size calculations are based on improvements (from baseline to 1-year) in VAS pain score and total KOOS. KOOS total score was used as a proxy and should ensure the study is amply powered.</p> <p>Considering a 10-point scale, assuming a decline of 1 point on average in pain in the Control arm (corticosteroids) and a decline on average of 2.5 points in a treatment arm (mesenchymal stem cells) and an estimated standard deviation on change of 3.5, the proposed sample sizes (n=121 subjects per group or 484 total subjects) will provide 91% power to detect a difference on change of 1.5 points at the two-sided 5% significance level if the true difference between treatment arms is 1.5 points (two-sided two-sample equal variance t-test).</p> <p>Assuming an increase of 10 points on average in total KOOS in the Control arm (corticosteroids) and an increase on average of 20 points in a treatment arm (mesenchymal stem cells) and an estimated standard deviation on change of 20, the proposed sample sizes (n=121 subjects per group or 484 total subjects) will provide 97% power to detect a difference on change of 10 points at the two-sided 5% significance level if the true difference between treatment arms is 10 points (two-sided two-sample equal variance t-test).</p> <p>Each of the four participating sites will accrue 30 subjects to each of the 4 treatment arms. Cohort retention is expected to be 90% at 1-year.</p>
Data exclusions	<p>The Per-Protocol Population (PP) includes subjects in the ITT population without any major protocol deviations. A major protocol deviation is a deviation that may significantly impact the completeness, accuracy, and/or reliability of the trial data; that may significantly affect a subject's rights, safety, or well-being (ICH E3 R1 Guidelines 2013).</p>
Replication	<p>The primary analyses of the data were performed according to subjects' original treatment assignment (i.e., intention-to-treat analyses) regardless of their compliance and the inclusion of all data from all subjects randomized in the final analysis. Sensitivity analyses were used to ensure our results were robust. Observed case (secondary) and multiple imputation methods (primary) were used for the primary ITT efficacy analysis</p>
Randomization	<p>The study includes a parallel design using a blocked central randomization scheme of 1:1:1:1. Subjects, who have provided written informed consent, will be randomized to one of the following treatment arms: Arm 1 includes randomization to bone marrow derived MSCs versus corticosteroid injection.</p> <p>Arm 2 includes randomization to adipose derived MSCs versus corticosteroid injection.</p> <p>Arm 3 includes randomization to umbilical cord tissue MSC's versus corticosteroid injection. Four hundred eighty subjects will be randomly assigned to treatments ensuring the trial is single-blind with a 1:1:1:1 allocation ratio across the four treatment arms. One hundred twenty subjects will be randomized at each of 4 clinical sites.</p> <p>Arm 1: Forty subjects will be randomized with a 3:1 allocation ratio (bone marrow derived MSCs versus corticosteroid injection; 30:10). This same implementation plan will be used to randomize 40 subjects to Arm 2 (adipose derived MSCs versus corticosteroid injection) with a 3:1 allocation ratio and to randomize 40 subjects to Arm 3 (umbilical cord tissue MSC's versus corticosteroid injection) with a 3:1 allocation ratio.</p>
Blinding	<p>As a single-blinded study, the site principal investigators were not required to be blinded, however subjects were blinded to their injection. The blinding was implemented by limiting visualization of the syringe contents with opaque covering.</p>

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.



## Materials &amp; experimental systems

- n/a  Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Clinical data
- Dual use research of concern

## Methods

- n/a  Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	ClinicalTrials.gov Identifier number is NCT03818737.
Study protocol	Full study protocol included with manuscript submission and in the public domain on the clinicaltrials.gov site
Data collection	570 patients were screened to identify 480 eligible patients that were randomized at five clinical sites in five different states within the United States of America. The first subject was enrolled in March 2019 and last subject completed the study in June 2022.
Outcomes	The primary efficacy co-outcomes are: a change in the visual analog score (VAS) pain score and a change in the pain subsection of the knee injury and osteoarthritis outcome (KOOS) score. Secondary outcomes include change in total KOOS score, EuroQuality of Life (EQ5D 3L) and Patient-Reported Outcomes Measurement Information System (PROMIS 29). Changes in MRI biomarkers of cartilage and joint health between the four treatment groups will be compared.

## Magnetic resonance imaging

## Experimental design

Design type	Absolute change in MRI Score from baseline to month 12 will be analyzed using an ANCOVA
Design specifications	site, treatment arm and baseline MRI Score as fixed effects; the p-values for the treatment comparison, estimates of the treatment difference and the 95% confidence interval of the difference will be generated from the ANCOVA model.
Behavioral performance measures	No behavioral performance measures were taken

## Acquisition

Imaging type(s)	Structural (morphologic sequences) and biochemical (T2 map sequence)
Field strength	3-Tesla
Sequence & imaging parameters	For structural MRI, we used 2D fast spin echo in axial, coronal, and sagittal planes, without and with fat suppression. For biochemical MRI, we used 2D fast spin echo multi-echo sequence to determine T2 relaxation values in cartilage and menisci.
Area of acquisition	whole knee joint
Diffusion MRI	<input type="checkbox"/> Used <input checked="" type="checkbox"/> Not used

## Preprocessing

Preprocessing software	No preprocessing software was used
Normalization	No normalization was performed
Normalization template	No normalization template was used
Noise and artifact removal	No Noise and artifact removal was performed
Volume censoring	No volume censoring was performed

## Statistical modeling & inference

Model type and settings	For T2 mapping, we used a mono-exponential T2 decay model
Effect(s) tested	The Difference of Absolute Change in MRI Cartilage Loss Extent Score from Baseline between each treatment group (3) and the CSI (control) group.
Specify type of analysis:	<input type="checkbox"/> Whole brain <input checked="" type="checkbox"/> ROI-based <input type="checkbox"/> Both
Anatomical location(s)	manual segmentation was used
Statistic type for inference (See <a href="#">Eklund et al. 2016</a> )	Score as response variable and site, treatment arm and baseline MRI score as fixed effects.
Correction	Hochberg adjustment method is used: order the p-values from high to low and compare the largest p value to 0.05, the middle p value to 0.05/2, and the smallest p value to 0.05/3. This is used to compare LS Means of the Difference of Absolute Change in MRI Cartilage Loss Extent Score from Baseline between each treatment group (3) and the CSI (control) group.

## Models & analysis

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Functional and/or effective connectivity
<input checked="" type="checkbox"/>	<input type="checkbox"/> Graph analysis
<input type="checkbox"/>	<input checked="" type="checkbox"/> Multivariate modeling or predictive analysis
Multivariate modeling and predictive analysis	Ancova model with MRI Score at each visit as dependent variable No extraction or dimension reduction No training No evaluation